key: cord-0963131-zx2ll21u
authors: Ochoa‐Grullón, Juliana; Peña Cortijo, Ascensión; Guevara‐Hoyer, Kissy; Jiménez García, Carlos; de la Fuente, Eduardo; de la Peña, Antonia Rodríguez; Fernández‐Arquero, Miguel; González Fernández, Ata; Sánchez‐Ramón, Silvia
title: B‐cell haematological malignancies and SARS‐CoV‐2 infection: Could immunological interventions influence the outcome?
date: 2021-06-19
journal: EJHaem
DOI: 10.1002/jha2.249
sha: b73b96cd5383c532c01251c5670cc252a4b625c2
doc_id: 963131
cord_uid: zx2ll21u

B cell haematological malignancies (HMs) have been described as the worst cancer type for concomitant COVID‐19 in terms of mortality, with rates up to 65%. This risk factor for COVID‐19 cannot only be explained by comorbidities and advanced age of patients, but aggravated by secondary immunodeficiency (SID). We aimed at evaluating the impact of COVID‐19 on 86 HM patients with concomitant SID from a single centre. Only 14 HM patients of 86 (16.28%) patients suffered COVID‐19, with mortality rate of 7%. When we considered patients according to B‐cell defect only or multiple immune defect overlap (B‐T‐cell/NK cells/complement), patients with immune defect overlap presented 5.30‐fold higher risk of COVID‐19 than only B cell defect (95% CI, 1.67–17.0) (p = 0.004). Seven (50%) patients were on active IgRT; while five (36%) had received prior mucosal vaccines for respiratory infections. Our results show that modelling SID in HM may contribute to better prediction of infectious risk and to prompt more targeted and timely preventive therapies.

According to different studies, case fatality rate for SARS-CoV-2 virus infection (COVID-19) in B cell hematologic malignancy (HM) ranges between 14% and 65% depending on patient's age and need of intensive care unit (ICU) intervention, an extremely high rate considering the 6%-8% mortality among age-adjusted patients without cancer [1] [2] [3] . Pre-existing co-morbidities (older age, chronic lung/heart disease, obesity, diabetes, hypertension) contribute to a more severe course of the disease [4] . In general terms, HM carries an excess risk of infection due to secondary immunodeficiency (SID) that accounts for a significant proportion of mortality, both from underlying malignancy and chemotherapeutic protocols [5] . Numerous publications point to Age above 60 has been defined as the most important single aspect associated with high mortality. In our cohort, 64% (n = 9) were older than 60 years with mortality rate of 11%, a much lower frequency than that published so far (47%) in HM population [1] . [14] . IVIg seems to contain cross-reactive antibodies against SARS-CoV-2 due to common circulating coronaviruses [15] . The first plasma pool of IVIg that tested positive for anti-SARS-CoV-2 antibodies in Spain was in July 2020 [16] , and all infected patients were diagnosed during the first wave before July.

Immunomodulatory effects of IVIg both on innate and adaptive immunity might also have played a role [17, 18] . 

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

The outcome of COVID-19 in patients with hematological malignancy

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

Clinical characteristics of coronavirus disease 2019 in China

Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches

Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak

Characteristics of SARS-CoV-2 and COVID-19

When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach: When to initiate IgG therapy in antibody deficiency

Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin

Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy

Evaluation of polysaccharide typhim vi antibody response as a predictor of humoral immunodeficiency in haematological malignancies

Trained immunity-based vaccine in B cell hematological malignancies with recurrent infections: a new therapeutic approach

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Clinical course and outcomes of critically Ill patients with Middle East respiratory syndrome coronavirus infection

Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products

Intravenous immunoglobulins at the crossroad of autoimmunity and viral infections

IVIg promote crosstolerance against inflammatory stimuli in vitro and in vivo

B-cell haematological malignancies and SARS-CoV-2 infection: Could immunological interventions influence the outcome?

We are indebted to the outstanding and selfless dedication of all the health professionals during this pandemic. We are grateful to the